6-(Cyclopropylmethoxy)pyrimidin-4-amine 、 环戊醇 、 以6-(cyclopentyloxy)pyrimidin-4-amine (0.238 g, 1.328 mmol, 86% yield) was obtained as a white solid的产率得到6-(cyclopentyloxy)pyrimidin-4-amine
参考文献:
名称:
BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS
[EN] QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉ DE QUINUCLIDINE COMME LIGANDS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 DE L'ACÉTYLCHOLINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2011053292A1
公开(公告)日:2011-05-05
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
申请人:Cook, II James H.
公开号:US20090270405A1
公开(公告)日:2009-10-29
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
[EN] BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS<br/>[FR] COMPOSÉS DE SULFONAMIDES BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU CANAL SODIQUE
申请人:AMGEN INC
公开号:WO2014201206A1
公开(公告)日:2014-12-18
The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
申请人:Cook, II James H.
公开号:US20100099684A1
公开(公告)日:2010-04-22
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
Bicyclic sulfonamide compounds as sodium channel inhibitors
申请人:AMGEN INC.
公开号:US09212182B2
公开(公告)日:2015-12-15
The present invention provides compounds of Formula I,
and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.